Pharma plant for sale in India, checked before it reaches you.
Running GMP and WHO-GMP manufacturing units for sale and on rent across Himachal Pradesh, Uttarakhand and Haryana. Every listing is screened for licence validity, section-wise approvals, land title and Revised Schedule M readiness before it is published, by a team that has sat on the other side of the audit.
Position as of August 2026. Ten units are published below with full specifications; the balance of the verified inventory is off-market and released only under NDA at the owner's instruction.
Ten pharmaceutical manufacturing units are currently listed for sale or rent in India through Laafon Galaxy, from a ₹4.5 crore two-section liquid and ointment unit in Kala Amb to a ₹51 crore WHO-GMP oral solid dosage plant in Baddi and a ₹50 crore sterile injectable facility. Oral solid dosage units cluster in the ₹4.5–30 crore band; sterile and injectable capacity starts around ₹50 crore. Every listing states its licensed sections, certification scope, plot and built-up area, and whether the unit is running. Since 1 January 2026 the conditional Revised Schedule M extension for smaller manufacturers has closed, so a buyer now inherits full compliance exposure from day one.[2]
What changed on 1 January 2026, and why it repriced every plant
Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023 and took effect for manufacturers with turnover above ₹250 crore on 29 June 2024.[1] Smaller manufacturers who filed an upgradation plan received a conditional extension that ran only to 31 December 2025.[2] That window is now shut.
The practical effect on a transaction is direct. A unit that is not yet compliant is no longer a plant with time to upgrade; it is a plant carrying an open regulatory exposure that transfers with possession. Enforcement is not theoretical either. Risk-based inspections by CDSCO and state drug controllers had covered 905 units and produced 694 actions, including stop-production orders and licence suspensions, as reported in August 2025.[2] Schedule M readiness is now a price term, not a footnote, and it is the first thing checked on every unit listed here.
Ten verified units across three manufacturing states.
Filter by deal type, state, the sections you actually need approved, and budget. Every card links to the full dossier with licence scope, machinery and commercial detail.
Running WHO-GMP oral solid unit with 400+ third-party clients
Sterile injectable plant, small volume parenterals and ophthalmics
Carries a segregated beta-lactam injectable area with dedicated AHUs, alongside the general section. Confirm the cross-contamination controls against your own product plan before valuing it.
WHO-GMP oral solid dosage plant, 600+ approved formulations
Turn-key contract manufacturing facility, SIDCUL Pantnagar
Non-sterile only. No injectable, bulk drug or pesticide operations at site. Form 25 and Form 28 licences are active.
Running tablet, capsule, liquid and dry-syrup unit
WHO-GMP scope covers tablets and capsules only. Liquid orals and dry syrup are licensed but sit outside the WHO-GMP certificate, which matters if you intend to export from those sections.
Running unit with 450+ approved formulations, asset and licence sale
Not WHO-GMP certified. Suitable for domestic and third-party supply as it stands; budget for certification if regulated-market export is the plan.
GMP unit for tablets, capsules, liquids and external preparations
No hazardous, toxic or hormonal products handled at site, which keeps the changeover and cleaning validation burden low for a new owner.
Running unit, 250+ formulations and 30 third-party clients
Licensed by the Drugs Control Authority at Dharamshala. Schedule M design basis, but no WHO-GMP certificate disclosed. The lowest entry point here for a licensed oral solid dosage unit.
Two-section unit, liquid orals and topical preparations
Installed 2021, licence valid to 2027. Designed to WHO-GMP norms but certified GMP only. No tablet or capsule section, so plan for a fresh section approval if oral solids are the target.
Revised Schedule M compliant unit on rent, fastest route to first batch
Commissioned 2018 and upgraded for Revised Schedule M in 2025, so the compliance exposure that now sits on non-upgraded units has already been cleared here.
No published unit matches those filters. Off-market inventory that is not shown here changes weekly, so tell us the specification and we will check it against the unpublished list.
Looking to lease rather than buy? Units on rent in Baddi, Paonta Sahib, Kala Amb, Una, Haridwar, Roorkee, Ahmedabad and Vadodara move faster than sale inventory, so they are handled case by case on the pharma unit for rent page rather than listed here.
Buy running, buy closed, rent, or build from land.
Most buyers arrive convinced they want to purchase. About half of them are better served by a rental or a loan-licence arrangement for the first two years. The variable that decides it is rarely money, it is how soon you need a saleable batch.
Scroll the table sideways on a phone.
| Route | Typical capital | Time to first batch | Licence route | Main risk you carry |
|---|---|---|---|---|
| Buy a running unit | ₹4.5–51 Cr on current listings | 2 to 5 months | Fresh application or transfer formalities with the state licensing authority | Inherited compliance history, undisclosed liabilities, staff retention |
| Buy a closed or partly built unit | Land and shell cost, plus upgrade | 9 to 18 months | Fresh licence with fresh section approvals | Revised Schedule M upgrade cost is discovered after possession, not before |
| Rent a compliant unit | From about ₹4–6.5 lakh per month | 4 to 10 weeks | Loan licence, or your own licence on leased premises | No asset ownership, and dependence on the landlord holding compliance |
| Build greenfield | ₹5–15 Cr small oral solids, up to ₹170–355 Cr for sterile and API scale | 18 to 30 months | Full fresh licensing, layout approval, validation from zero | Time, cost overrun and a validation burden with no revenue against it |
Greenfield capital bands are drawn from our own 2026 cost breakdown, where a small domestic oral solids plant runs ₹5–15 crore, a mid-scale export-capable multi-formulation site ₹50–80 crore, and a large sterile or API facility ₹170–355 crore. Plant and machinery is 30 to 50 per cent of the total in every band. Work the numbers for your own configuration in the pharma plant setup cost calculator, or read the full pharma manufacturing plant cost breakdown for 2026.
Which route fits your constraint?
This is a starting position, not advice. Section approvals, product mix and the seller's compliance history all move the answer.
The screen a unit passes before it is published here.
These are the same categories a buyer's own diligence team works through. Doing them before listing is what removes the units that would have wasted your site visit.
- Manufacturing licence in Form 25 and Form 28, read against the original, with the issuing state authority and validity date noted
- Section-wise approvals, because a licence naming tablets does not automatically carry capsules, liquid orals or a segregated beta-lactam area
- GMP and WHO-GMP certificate scope, and specifically which sections the certificate actually covers, since partial scope is common and often misread as whole-plant certification
- Product permission list, matched against the formulations you intend to run
- Inspection and enforcement history, including any stop-production order, show-cause notice or suspension on record
- Revised Schedule M readiness across premises, flow, finishes and segregation, scored so the upgrade cost is known before the offer, not after possession
- HVAC and cleanroom classification, with AHU count, filtration stage and whether validation records exist and are current
- Purified water system, generation and storage capacity, loop design, and sanitisation and monitoring records
- Machinery inventory, make, capacity, year, condition and qualification status rather than a bare asset list
- Quality control laboratory, instrument qualification, method validation status and stability chamber capacity
- Title, whether freehold or on an industrial-estate lease, and what the lease permits on transfer
- Building plan approval and completion certificate, matched to what is physically standing on the plot
- Pollution control consent to establish and consent to operate, with validity and effluent category
- Encumbrance, charge and litigation search, including any bank charge sitting on plant and machinery
- Entity structure, since a partnership asset sale, a share transfer and a slump sale each carry different consequences for you
- Reason for sale, stated plainly, because a clean exit and a distressed exit are priced differently and both are legitimate
- Client concentration, since a unit with 400 third-party clients and one with 30 carry very different revenue risk after handover
- Turnover and margin basis, marked clearly as seller-stated until it is supported by filed accounts
- Key staff, particularly the approved technical staff, whose departure can stall production while replacements are approved
- Working capital and creditor position, separated from the asset price so you are not quietly funding someone else's payables
Running your own parallel check is sensible and we encourage it. The 50-point pharma plant acquisition checklist is the long-form version of the above, and the Revised Schedule M readiness check scores a unit against twelve inspection focus areas in about two minutes.
You are buying premises and approvals, not a portable licence.
A drug manufacturing licence in Form 25 or Form 28 is granted by the state licensing authority for specific premises and specific sections. It is not a company asset you can pick up and carry to another site, and it does not automatically follow a change of ownership. Depending on the state and on how the deal is structured, the route is either transfer formalities on the existing licence or a fresh application for the same premises. Applications and post-approval amendments for most categories now run through the Online National Drugs Licensing System operated by CDSCO with the states.[3]
Two consequences follow, and both are commercial rather than clerical. First, a share purchase and an asset purchase produce different licensing work, so the structure should be settled early rather than after heads of terms. Second, the gap between possession and a licence in your own name is real, and it is the single most common cause of a plant sitting idle after a completed purchase. We plan that gap into the timeline before the offer goes in.
Note also that a small set of categories, including certain parenterals and biologicals, involve central approval alongside the state licence. That is checked per unit, not assumed.
Five things that end a deal in diligence
- 01Certificate scope quietly narrower than the plant. A WHO-GMP certificate covering two sections presented as whole-site certification.
- 02Area figures that do not reconcile. A built-up area larger than the plot, or square feet and square metres used interchangeably.
- 03No Schedule M gap assessment. After 1 January 2026 an unassessed unit is an unpriced liability.
- 04Machinery under bank charge. Discovered late, it can strip the equipment out of the valuation you agreed.
- 05Seller-stated turnover with no filed accounts. Treat it as a hypothesis until the returns support it.
Where pharma plants actually come up for sale in India.
Formulation capacity is concentrated, and so is resale inventory. Knowing the cluster you are buying into matters as much as the unit itself, because it decides your labour pool, your vendor bench and your inspection environment.
Baddi, Nalagarh, Paonta Sahib, Kala Amb, Una
The deepest formulation cluster in North India and the source of most resale inventory, currently six of the ten units listed here. Baddi and Nalagarh in District Solan carry the larger WHO-GMP oral solid and sterile plants. Paonta Sahib and Kala Amb in District Sirmaur, and Tahliwal in District Una, sit at the smaller end, roughly ₹4.5 to 14 crore, which is where most first-time buyers land. Contract manufacturing vendors, engineers and qualified staff are all locally available, which shortens every timeline.
Haridwar, Roorkee, Bhagwanpur, Rudrapur and SIDCUL Pantnagar
The second cluster, built out around the SIDCUL integrated industrial estates. Plots are generally larger than in Himachal, and the units listed here run ₹11 to 30 crore with WHO-GMP scope at the upper end. Bhagwanpur near Roorkee sits about 195 km from Delhi NCR, and Rudrapur in District Udham Singh Nagar gives good access to the eastern distribution corridor.
Rewari and the NH-48 corridor
Thinner on sale inventory but strong for rental and loan-licence arrangements, because proximity to Delhi NCR suits companies that want manufacturing close to their commercial team. The Rewari unit listed here was upgraded for Revised Schedule M in 2025, which is increasingly the deciding factor in this corridor.
Gujarat, principally Ahmedabad and Vadodara, is the other major cluster. We do not currently hold published sale inventory there, and we would rather say so than list a unit we have not screened.
List your plant confidentially.
Your identity and your plant details are never published without written consent. Buyer requirements are shared only after intent is verified, and an NDA is available before any document changes hands.
Before you buy or sell.
Work through the numbers before you make an offer
-
50-point pharma plant acquisition checklist
The long-form due-diligence framework behind the screen above, scored high, medium and low against remediation cost and timeline.
-
Revised Schedule M readiness check
Score a unit against twelve inspection focus areas in about two minutes. Runs on your device, nothing is submitted.
-
Pharma manufacturing plant cost in India, 2026 breakdown
Component-level capital costs by plant tier, with the location factors and government incentive schemes that move them.
-
Pharma plant setup cost calculator
Enter sections, daily capacity, state and compliance standard, and compare Revised Schedule M against WHO-GMP and EU-GMP for the same configuration.
-
Pharma unit for rent in India
The rental and loan-licence route, with the clusters where leased capacity is actually available.
- [1]Central Drugs Standard Control Organisation. Gazette Notifications: G.S.R. 922(E), Notification of Schedule M of the Drugs Rules 1945, 28 December 2023. New Delhi: Ministry of Health and Family Welfare. Available from: cdsco.gov.in Gazette Notifications. Accessed August 2026.
- [2]Ministry of Health and Family Welfare, Government of India. Steps taken to Prevent Sale of Adulterated Drugs. Press Information Bureau; 12 August 2025. Available from: pib.gov.in press release. Accessed August 2026.
- [3]Central Drugs Standard Control Organisation. Online National Drugs Licensing System (ONDLS), One Nation One Drug Licensing System. Ministry of Health and Family Welfare. Available from: statedrugs.gov.in. Accessed August 2026.
This page is technical and educational information for pharmaceutical professionals evaluating a manufacturing asset. It is not legal, regulatory, medical or investment advice. Listing specifications are drawn from each unit's dossier and from seller-supplied documents, and financial figures marked as seller-stated remain unverified until supported by filed accounts. Indian statutory instruments, pharmacopoeial texts, licence conditions and state-level practice change frequently, so confirm the current position with the relevant licensing authority and take your own professional advice before committing to a transaction. Verify every specification independently during due diligence.
Tell us the specification and we will match it, published or not.
State, sections, budget and timeline. If nothing on this page fits, the off-market list usually does.